User profiles for "author:Devin Abrahami"
Devin AbrahamiMcGill University Verified email at mail.mcgill.ca Cited by 453 |
Proton pump inhibitors and risk of gastric cancer: population-based cohort study
Objective To determine whether new users of proton pump inhibitors (PPIs) are at an
increased risk of gastric cancer compared with new users of histamine-2 receptor …
increased risk of gastric cancer compared with new users of histamine-2 receptor …
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
D Abrahami, A Douros, H Yin, OHY Yu, C Renoux… - bmj, 2018 - bmj.com
Objective To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with
the incidence of inflammatory bowel disease in patients with type 2 diabetes. Design …
the incidence of inflammatory bowel disease in patients with type 2 diabetes. Design …
Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study
Objective To examine proton pump inhibitor (PPI) and histamine-2 receptor antagonist
(H2RA) prescribing patterns over a 29-year period by quantifying annual prevalence and …
(H2RA) prescribing patterns over a 29-year period by quantifying annual prevalence and …
Proton pump inhibitors and risk of colorectal cancer
Objective To determine whether proton pump inhibitors (PPIs) are associated with an
increased risk of colorectal cancer, compared with histamine-2 receptor antagonists …
increased risk of colorectal cancer, compared with histamine-2 receptor antagonists …
Sodium–glucose cotransporter 2 inhibitors and the short-term risk of bladder cancer: an international multisite cohort study
D Abrahami, H Tesfaye, H Yin, S Vine, B Hicks… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE To determine whether sodium–glucose cotransporter 2 (SGLT2) inhibitors,
compared with glucagon-like peptide 1 receptor agonists (GLP-1RAs) or dipeptidyl …
compared with glucagon-like peptide 1 receptor agonists (GLP-1RAs) or dipeptidyl …
Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
Objective To determine whether use of dipeptidyl peptidase-4 (DPP-4) inhibitors and
glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of …
glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk of …
Statins and lower mortality in rheumatic diseases: An effect of immortal time bias?
D Abrahami, M Hudson, S Suissa - Seminars in Arthritis and Rheumatism, 2021 - Elsevier
Objective Randomized controlled trials of the effectiveness of statins on rheumatic disease
outcomes have shown limited or no benefit. On the other hand, observational studies have …
outcomes have shown limited or no benefit. On the other hand, observational studies have …
Sodium–glucose cotransporter 2 inhibitors and the risk of fractures among patients with type 2 diabetes
D Abrahami, A Douros, H Yin, OHY Yu… - Diabetes Care, 2019 - Am Diabetes Assoc
The association between sodium–glucose cotransporter 2 (SGLT2) inhibitors and the risk of
fractures is controversial. In the Canagliflozin Cardiovascular Assessment Study (CANVAS) …
fractures is controversial. In the Canagliflozin Cardiovascular Assessment Study (CANVAS) …
Use of real‐world data to emulate a clinical trial and support regulatory decision making: assessing the impact of temporality, comparator choice, and method of …
D Abrahami, R Pradhan, H Yin, P Honig… - Clinical …, 2021 - Wiley Online Library
External controls have been primarily used in the setting of single‐arm trials of rare
diseases; their use in common diseases has not been readily investigated, nor is there …
diseases; their use in common diseases has not been readily investigated, nor is there …
Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study
D Abrahami, R Pradhan, H Yin, R Yanofsky… - Gut, 2023 - gut.bmj.com
Objective To determine whether the use of proton pump inhibitors (PPIs) compared with the
use of histamine-2 receptor antagonists (H2RAs) is associated with an increased risk of …
use of histamine-2 receptor antagonists (H2RAs) is associated with an increased risk of …